Neoadjuvant chemotherapy for hypopharyngeal carcinoma

Masato Fujii; Tatsuo Matsunaga; Koichi Tsunoda; Kunio Mizutari; Ryoiti Fujii; Kanako Masuda; Satoko Kimura; Toshiki Tomita; Hiroyuki Ozawa; Takekatsu Fujimine

doi:10.5981/jjhnc.31.363

Neoadjuvant chemotherapy for hypopharyngeal carcinoma

Masato Fujii, Tatsuo Matsunaga, Koichi Tsunoda, Kunio Mizutari, Ryoiti Fujii, Kanako Masuda, Satoko Kimura, Toshiki Tomita, Hiroyuki Ozawa, Takekatsu Fujimine

Department of Otorhinolaryngology

Research output: Contribution to journal › Article › peer-review

Abstract

The prognosis of patients with advanced hypopharyngeal carcinoma (HPC) is poor. Many studies about chemoradiation for advanced head and neck carcinoma report significant benefit for survival. They also prove improved survival rate equal to radical surgery. Chemotherapy and radiotherapy contribute to functional preservation for head and neck cancer. Some studies report survival benefit with neoadjuvant chemotherapy (NAC) for unresectable head and neck squamous cell carcinoma (HNSCC). Combination chemotherapy with CDDP, 5FU, and Docetaxel (TPF) shows strong effect for HNSCC. We studied NAC with TPF for advanced HNSCC. The response rate was 76.5% for 51 assessable patients. Patients with advanced HPC showed high response rate of 86.4%. NAC responders treated with chemoradiation showed good prognoses with larynx and hypopharynx preservation. NAC with TPF will play an important role in developing a new strategy for advanced HPC.

Original language	English
Pages (from-to)	363-368
Number of pages	6
Journal	Toukeibu Gan
Volume	31
Issue number	3
DOIs	https://doi.org/10.5981/jjhnc.31.363
Publication status	Published - 2005 Jan 1

Keywords

combination chemotherapy
hypopharyngeal carcinoma
neoadjuvant chemotherapy

ASJC Scopus subject areas

Otorhinolaryngology
Oncology

Access to Document

10.5981/jjhnc.31.363

Fingerprint Dive into the research topics of 'Neoadjuvant chemotherapy for hypopharyngeal carcinoma'. Together they form a unique fingerprint.

Cite this

@article{e1a9f25780d245329f23183e43626f25,

title = "Neoadjuvant chemotherapy for hypopharyngeal carcinoma",

abstract = "The prognosis of patients with advanced hypopharyngeal carcinoma (HPC) is poor. Many studies about chemoradiation for advanced head and neck carcinoma report significant benefit for survival. They also prove improved survival rate equal to radical surgery. Chemotherapy and radiotherapy contribute to functional preservation for head and neck cancer. Some studies report survival benefit with neoadjuvant chemotherapy (NAC) for unresectable head and neck squamous cell carcinoma (HNSCC). Combination chemotherapy with CDDP, 5FU, and Docetaxel (TPF) shows strong effect for HNSCC. We studied NAC with TPF for advanced HNSCC. The response rate was 76.5% for 51 assessable patients. Patients with advanced HPC showed high response rate of 86.4%. NAC responders treated with chemoradiation showed good prognoses with larynx and hypopharynx preservation. NAC with TPF will play an important role in developing a new strategy for advanced HPC.",

keywords = "combination chemotherapy, hypopharyngeal carcinoma, neoadjuvant chemotherapy",

author = "Masato Fujii and Tatsuo Matsunaga and Koichi Tsunoda and Kunio Mizutari and Ryoiti Fujii and Kanako Masuda and Satoko Kimura and Toshiki Tomita and Hiroyuki Ozawa and Takekatsu Fujimine",

year = "2005",

month = jan,

day = "1",

doi = "10.5981/jjhnc.31.363",

language = "English",

volume = "31",

pages = "363--368",

journal = "Japanese Journal of Head and Neck Cancer",

issn = "1349-5747",

publisher = "Nihon Tokeibu Gan Gakkai",

number = "3",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy for hypopharyngeal carcinoma

AU - Fujii, Masato

AU - Matsunaga, Tatsuo

AU - Tsunoda, Koichi

AU - Mizutari, Kunio

AU - Fujii, Ryoiti

AU - Masuda, Kanako

AU - Kimura, Satoko

AU - Tomita, Toshiki

AU - Ozawa, Hiroyuki

AU - Fujimine, Takekatsu

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The prognosis of patients with advanced hypopharyngeal carcinoma (HPC) is poor. Many studies about chemoradiation for advanced head and neck carcinoma report significant benefit for survival. They also prove improved survival rate equal to radical surgery. Chemotherapy and radiotherapy contribute to functional preservation for head and neck cancer. Some studies report survival benefit with neoadjuvant chemotherapy (NAC) for unresectable head and neck squamous cell carcinoma (HNSCC). Combination chemotherapy with CDDP, 5FU, and Docetaxel (TPF) shows strong effect for HNSCC. We studied NAC with TPF for advanced HNSCC. The response rate was 76.5% for 51 assessable patients. Patients with advanced HPC showed high response rate of 86.4%. NAC responders treated with chemoradiation showed good prognoses with larynx and hypopharynx preservation. NAC with TPF will play an important role in developing a new strategy for advanced HPC.

AB - The prognosis of patients with advanced hypopharyngeal carcinoma (HPC) is poor. Many studies about chemoradiation for advanced head and neck carcinoma report significant benefit for survival. They also prove improved survival rate equal to radical surgery. Chemotherapy and radiotherapy contribute to functional preservation for head and neck cancer. Some studies report survival benefit with neoadjuvant chemotherapy (NAC) for unresectable head and neck squamous cell carcinoma (HNSCC). Combination chemotherapy with CDDP, 5FU, and Docetaxel (TPF) shows strong effect for HNSCC. We studied NAC with TPF for advanced HNSCC. The response rate was 76.5% for 51 assessable patients. Patients with advanced HPC showed high response rate of 86.4%. NAC responders treated with chemoradiation showed good prognoses with larynx and hypopharynx preservation. NAC with TPF will play an important role in developing a new strategy for advanced HPC.

KW - combination chemotherapy

KW - hypopharyngeal carcinoma

KW - neoadjuvant chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85009592456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009592456&partnerID=8YFLogxK

U2 - 10.5981/jjhnc.31.363

DO - 10.5981/jjhnc.31.363

M3 - Article

AN - SCOPUS:85009592456

VL - 31

SP - 363

EP - 368

JO - Japanese Journal of Head and Neck Cancer

JF - Japanese Journal of Head and Neck Cancer

SN - 1349-5747

IS - 3

ER -